Teva to Present New Analyses of AJOVY® (fremanezumab-vf

16 presentations will examine safety and efficacy of AJOVY and AUSTEDOTEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for two of the company’s neurology portfolio treatments, AJOVY® (fr...

Related Keywords

United States , Israel , America , American , Yael Ashman , Denisa Hurtukova , A Survey Of Patients , Drug Administration , Teva Pharmaceuticals , Teva Pharmaceutical Industries Ltd , Head Of North America Medical Affairs , Health Care Resource Utilization , American Academy Of Neurology , Baseline Abnormal Involuntary Movement Scale Item , Teva Pharmaceutical Industries , American Academy , Annual Meeting , North America Medical , Month Safety , Pooled Analysis , Disability Outcomes , Pooled Results , Placebo Controlled Phase , Acute Medication Use , Migraine Initiating Fremanezumab , Database Analysis , Migraine Related Health Care Resource Utilization , Patients Initiating Fremanezumab , Health Care Costs , Patients Suffering With Migraine , Southern Israel , Retrospective Database Analysis , Injection Site Adverse Events With Fremanezumab , Heart Rate , Blood Pressure , Participants Treated With Fremanezumab , Retrospective Database Study , Patients With Migraine , Preventive Treatment , Different Racial , Ethnic Subgroups , Unstructured Electronic Medical Record Data , Tardive Dyskinesia , Long Term Deutetrabenazine Treatment , Patients With Tardive Dyskinesia , Underlying Psychiatric , Mood Disorders , Term Efficacy , Concomitant Dopamine Receptor Antagonist Use , Social Aspects , Patient Lives , Safety Information , Adverse Events , Malignant Syndrome , Melanin Containing Tissues , Adverse Reactions , Prescribing Information , Pharmaceutical Industries , Private Securities Litigation Reform Act , Annual Report ,